替代癌症治疗市场-全球行业规模、份额、趋势、机会、预测，2018-2028 年，按治疗类型、按疾病类型、按最终用户、按地区、竞争

全球癌症替代疗法市场有望在预测期内实现显着增长。

其背景是老龄化社会的到来，更容易患上各种类型的癌症。 此外，老龄化社会对新疗法的认识不断提高，以及市场进入者数量的增加，也是预测期内进一步推动市场增长的主要因素。 此外，用于疼痛管理的针灸、芳香疗法和瑜伽等替代疗法的迅速普及将进一步推动预测期内的市场增长。 此外，增加替代癌症治疗的保险范围以及政府组织增加对人们进行新疗法教育的举措预计将推动多年来的市场增长。

癌症患病率增加

世界上大多数人对酒精、烟草和不健康食品的消费增加了腺癌、淋巴瘤、胃肠道间质瘤、肺癌和乳腺癌的发病率。它推动了预测期内的市场增长。 同样，易患胃癌等慢性病的老年人口不断增加，胃癌是全球老年男性中最常见的癌症杀手之一，将在预测期内推动市场增长。我猜。 2022 年，美国国家癌症研究所估计，美国将有大约 26,380 例胃癌新病例和 11,090 例胃癌死亡病例。 在发展中国家，男性比女性更容易患胃癌。 不仅在北美地区，而且在世界各个地区，胃癌患病率的上升增加了对治疗患者的有效疗法的需求，这推动了预测期内的市场增长。预计将鼓励增长。 例如，根据加拿大癌症协会公布的2021年统计数据，预计2021年将有4000名加拿大人患上胃癌。 同样，多年来政府为促进采用替代癌症治疗而采取的更多举措也促进了市场增长。 此外，印度阿尤什部由印度政府设立，负责调查与自然疗法、阿育吠陀和顺势疗法药物的教育、产品和研究相关的事宜。 因此，政府对替代疗法增长的投资不断增加，推动了对各种补充和替代癌症疗法的需求。

医疗支出增加

由于医疗保健行业研发部门的技术不断发展以及癌症诊断中替代疗法的利用，预计在预测期内对替代癌症疗法的需求将产生可观的增长。 同样，私人和政府机构在製药和生物技术公司的支持下支持研发部门，这进一步推动了预测期内的市场增长。 癌症研究的资金正在迅速增加，其中大部分政府资金用于乳腺癌和儿童癌症。 2019 年，美国国立卫生研究院 (NIH) 在乳腺癌方面的投资为 4.6 亿美元，到 2022 年将增加到 35 亿美元。

近期发展

• 2018 年 2 月，加拿大卫生部宣布，Janssens Zytiga 与泼尼松联合使用已接受长达 3 个月的雄激素剥夺治疗的新诊断高危转移性激素敏感性前列腺癌患者获得批准和雄激素剥夺疗法治疗
• 2020 年 4 月，美国 FDA 批准 Trodelvy (sacituzumab govitecan-hziy) 用于治疗成年三阴性乳腺癌患者。 Trodelvy 是一种 Trop-2 共免疫和拓扑异构□抑製剂製剂，专注于 Trop-2 受体，有助于癌症的发生、分离和扩散。

可用的自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

• 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

• 市场定义
• 市场范围
  • 目标市场
  • 研究目标年份
  • 主要市场细分

第二章研究方法论

• 调查目的
• 基线调查方法
• 主要行业合作伙伴
• 主要协会和次要信息
• 调查方法
• 数据三角测量和验证
• 假设和限制

第 3 章执行摘要

• 市场概览
• 主要市场细分概述
• 主要市场参与者概览
• 主要地区/国家概览
• 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第五章全球抗癌替代药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按疗法类型（激素疗法、针灸、营养补充剂等）
  • 按疾病分类（胃肠癌、肺癌、乳腺癌、结直肠癌、白血病、淋巴瘤、黑色素瘤、前列腺癌等）
  • 按最终用户（医院/诊所、癌症/放射治疗中心、家庭护理等）
  • 按地区
  • 按公司分类（2022 年）
• 产品地图
  • 按治疗类型
  • 按疾病类型
  • 最终用户
  • 按地区

第六章北美抗癌替代药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按疗法类型（激素疗法、针灸、营养补充剂等）
  • 按疾病分类（胃肠癌、肺癌、乳腺癌、结直肠癌、白血病、淋巴瘤、黑色素瘤、前列腺癌等）
  • 按最终用户（医院/诊所、癌症/放射治疗中心、家庭护理等）
  • 按国家
• 北美：国家/地区分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲抗癌替代药物市场前景

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按疗法类型（激素疗法、针灸、营养补充剂等）
  • 按疾病分类（胃肠癌、肺癌、乳腺癌、结直肠癌、白血病、淋巴瘤、黑色素瘤、前列腺癌等）
  • 按最终用户（医院/诊所、癌症/放射治疗中心、家庭护理等）
  • 按国家
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第 8 章亚太替代抗癌药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按疗法类型（激素疗法、针灸、营养补充剂等）
  • 按疾病分类（胃肠癌、肺癌、乳腺癌、结直肠癌、白血病、淋巴瘤、黑色素瘤、前列腺癌等）
  • 按最终用户（医院/诊所、癌症/放射治疗中心、家庭护理等）
  • 按国家
• 亚太地区：国家/地区分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳大利亚

第9章南美抗癌替代药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按疗法类型（激素疗法、针灸、营养补充剂等）
  • 按疾病分类（胃肠癌、肺癌、乳腺癌、结直肠癌、白血病、淋巴瘤、黑色素瘤、前列腺癌等）
  • 按最终用户（医院/诊所、癌症/放射治疗中心、家庭护理等）
  • 按国家
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章中东和非洲的替代抗癌药物市场前景

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按疗法类型（激素疗法、针灸、营养补充剂等）
  • 按疾病分类（胃肠癌、肺癌、乳腺癌、结直肠癌、白血病、淋巴瘤、黑色素瘤、前列腺癌等）
  • 按最终用户（医院/诊所、癌症/放射治疗中心、家庭护理等）
  • 按国家
• MEA：国家分析
  • 南非替代抗癌药
  • 沙特阿拉伯癌症替代疗法
  • 阿联酋替代抗癌药

第 11 章市场动态

• 司机
  • 癌症患者增加
  • 不断增长的医疗支出
• 做
  • 缺乏对新疗法的认识
  • 昂贵的医疗费用

第12章市场趋势与发展

• 近期发展状况
• 併购
• 产品发布

第 13 章全球抗癌替代药物市场：SWOT 分析

第 14 章波特的五力分析

• 行业竞争
• 新进入的可能性
• 供应商的力量
• 客户力量
• 替代品的威胁

第15章竞争格局

• 业务概览
• 提供的产品
• 近期发展状况
• 财务（据报导）
• 主要人物
• SWOT 分析
  • Innovative Medicine, LLC
  • Northwest Natural Health Clinic
  • Immunotherapy Institute
  • Georgia Cancer Specialists
  • Holistic Bio Spa
  • Johnson & Johnson
  • Celgene Corporation
  • Astellas Pharma, Inc.
  • Novartis AG
  • Merck KGaA

第16章 策略建议

Global Alternative Cancer Therapeutics market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the rising aging population, which is susceptible to different types of cancers. Additionally, the growing number of market players, along with growing awareness of new therapies among the aging population, is a major factor that will further drive the growth of the market during the forecast period. Also, the rapidly growing adoption of new therapies such as acupuncture, aromatherapy, yoga, and other alternative therapies for pain management will further drive the growth of the market in the forecast period. Also, growing insurance coverage for alternative cancer treatment, along with growing initiatives by government organizations to educate people about new therapy, will drive the growth of the market over the years.

Growing Prevalence of Cancer

The increasing incidence of adenocarcinoma, lymphoma, and gastrointestinal stromal tumors, lung cancer, breast cancer due to the consumption of alcohol, tobacco, and unhealthy food by the majority of the population across the world is driving the market growth during the forecast period. Similarly, the rising aging population, which is susceptible to chronic diseases like stomach cancer, one of the most common deadly cancers worldwide among older males, will boost the market growth in the forecast period. In 2022 the National Cancer Institute estimated around 26,380 new stomach cancer cases and 11,090 deaths in the United States. In developing countries, stomach cancer is diagnosed more in males than females. The increasing prevalence of gastric cancer across the North American region and also across different parts of the globe has increased the demand for effective therapies for treating patients, which in turn is expected to propel the market growth during the forecast period. For instance, according to the 2021 statistics published by the Canadian Cancer Society, 4,000 Canadians were estimated to develop gastric cancer in 2021. Similarly, growing initiatives by the government to promote the adoption of alternative cancer therapeutics are also boosting the growth of the market over the years. Also, the Ministry of Ayush in India was set up by the government of India to look into matters related to the education, product, and research of naturopathy, Ayurveda, and homeopathy medicines. Therefore, the rising government investments in the growth of alternative therapies is fuelling the demand for various complementary and alternative cancer treatment.

Rising Healthcare Expenditure

Due to the increasing technological developments in the research and development sector in the healthcare industry and the use of alternative therapies in cancer diagnosis, the demand for alternative cancer therapy is expected to create a lucrative growth in the forecast period. Similarly, private and government organizations are supporting the research and development sector with the help of pharmaceutical and biotechnology firms which is further boosting the market growth in the forecast period. The funding for cancer research is rapidly increasing, and most of the government funding is for breast cancer and childhood cancer. In 2019 the National Institutes of Health (NIH) invested USD460 million in breast cancer, which increased to USD3.5 billion in the year 2022.

Market Segmentation

Global alternative cancer therapeutics market can be segmented on therapy type, disease type, end users, region, and competitive landscape. Based on the therapy type, the market can be segmented into Hormone Therapies, Acupuncture, and Dietary Supplements, among Others. Based on Diseases Type, the market can be segmented into Gastrointestinal, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Melanoma, Prostate Cancer, and Others. Based on the End Users, the market can be differentiated into Hospitals and Clinics, cancer and Radiation Therapy Centers, Home Care, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global alternative cancer therapeutics market on account of the increasing incidence of different types of cancer in the country.

Recent Developments

• In February 2018, Health Canada approved Janssens Zytiga in combination with prednisone and androgen deprivation therapy for the treatment of patients with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer who have received up to three months of prior androgen deprivation therapy.

• In April 2020, the US FDA supported Trodelvy (sacituzumab govitecan-hziy) for the therapy of adult patients with triple-negative breast cancer. Trodelvy is a Trop-2-coordinated immunizer and topoisomerase inhibitor drug form which focuses on the Trop-2 receptor that helps cancer develop, separate, and spread.

Market Players

Innovative Medicine, LLC. , Northwest Natural Health Clinic, Immunotherapy Institute, Georgia Cancer Specialists, Holistic Bio Spa, Johnson & Johnson, Celgene Corporation, Astellas Pharma, Inc., Novartis AG, and Merck KGaA are some of the leading players operating in the Global Alternative Cancer Therapeutics Market.

Report Scope

In this report, global alternative cancer therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Alternative Cancer Therapeutics Market, By Therapy Type:

• Hormone Therapies
• Acupuncture and Dietary Supplements
• Others

Alternative Cancer Therapeutics Market, By Disease Type:

• Gastrointestinal
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia,
• Lymphoma
• Melanoma
• Prostate Cancer
• Others

Alternative Cancer Therapeutics Market, By End Users:

• Hospitals and Clinics
• Cancer and Radiation Therapy Center
• Home Care
• Others

Alternative Cancer Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alternative Cancer Therapeutics Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alternative Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Hormone Therapies, Acupuncture and Dietary Supplements, Others)
  • 5.2.2. By Disease Type (Gastrointestinal, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Melanoma, Prostate Cancer, Others)
  • 5.2.3. By End Users (Hospitals and Clinics, Cancer and Radiation Therapy Center, Home Care, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Map
  • 5.3.1. By Therapy Type
  • 5.3.2. By Disease Type
  • 5.3.3. By End Users
  • 5.3.4. By Region

6. North America Alternative Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type (Hormone Therapies, Acupuncture and Dietary Supplements, Others)
  • 6.2.2. By Disease Type (Gastrointestinal, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Melanoma, Prostate Cancer, Others)
  • 6.2.3. By End Users (Hospitals and Clinics, cancer and Radiation Therapy Center, Home Care, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Alternative Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Alternative Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Alternative Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By End User

7. Europe Alternative Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type (Hormone Therapies, Acupuncture and Dietary Supplements, Others)
  • 7.2.2. By Disease Type (Gastrointestinal, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Melanoma, Prostate Cancer, Others)
  • 7.2.3. By End Users (Hospitals and Clinics, cancer and Radiation Therapy Center, Home Care, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Alternative Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Alternative Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Alternative Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Alternative Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3.
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Alternative Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By End User

8. Asia-Pacific Alternative Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type (Hormone Therapies, Acupuncture and Dietary Supplements, Others)
  • 8.2.2. By Disease Type (Gastrointestinal, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Melanoma, Prostate Cancer, Others)
  • 8.2.3. By End Users (Hospitals and Clinics, cancer and Radiation Therapy Center, Home Care, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Alternative Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By End User
  • 8.3.2. India Alternative Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Alternative Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Alternative Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Alternative Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By End User

9. South America Alternative Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type (Hormone Therapies, Acupuncture and Dietary Supplements, Others)
  • 9.2.2. By Disease Type (Gastrointestinal, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Melanoma, Prostate Cancer, Others)
  • 9.2.3. By End Users (Hospitals and Clinics, cancer and Radiation Therapy Center, Home Care, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Alternative Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Alternative Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Alternative Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Alternative Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type (Hormone Therapies, Acupuncture and Dietary Supplements, Others)
  • 10.2.2. By Disease Type (Gastrointestinal, Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Melanoma, Prostate Cancer, Others)
  • 10.2.3. By End Users (Hospitals and Clinics, cancer and Radiation Therapy Center, Home Care, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Alternative Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Alternative Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Alternative Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1 Growing Prevalence of Cancer
  • 11.1.2 Growing Healthcare Expenditure
• 11.2. Challenges
  • 11.2.1 Lack of Awareness about New Therapies
  • 11.2.2 High Cost of Treatment

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Alternative Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (As Reported)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1. Innovative Medicine, LLC
  • 15.6.2. Northwest Natural Health Clinic
  • 15.6.3. Immunotherapy Institute
  • 15.6.4. Georgia Cancer Specialists
  • 15.6.5. Holistic Bio Spa
  • 15.6.6. Johnson & Johnson
  • 15.6.7. Celgene Corporation
  • 15.6.8. Astellas Pharma, Inc.
  • 15.6.9. Novartis AG
  • 15.6.10. Merck KGaA

16. Strategic Recommendations